Agenda Strawman – DAY 1

7:30-8:15 a.m.  Breakfast

8:30-8:45 a.m.  Welcome  Peter Davies  Diana Kerwin

8:45-8:50 a.m.  First Plenary Introduction  Luc Buee

8:50-9:20 a.m.  First Plenary  Jean-Pierre Brion

Tau Research: History and Current Status

Session 1:  Tauopathies
9:20-9:40 a.m.  Tau in Frontotemporal Dementias  Maria Spillantini
9:40-10 a.m.  NPC/Other Secondary Tauopathies  Marc Patterson

9:40-10 a.m.  Panel Discussion and Keynote  Irene Litvan

Moderator: Irene Litvan

10:20-10:45 a.m.  Break

Session 2:  Tau Imaging
10:45-11:05 a.m.  Overview of Tau Imaging  Keith Johnson
11:05-11:25 a.m.  Tau Imaging in Non AD Tauopathies  Gil Rabinovici
11:25-11:45 a.m.  Tauropography: What Does It Tell Us?  Gael Chetelat
11:45 a.m.-1:45 p.m.  Biomarker Lead for Semorinemab and [18F]GTP1 at Genentech  Kristin Wildsmith
12:05 p.m.  Panel Discussion  Margaret Sutherland

Moderator: Margaret Sutherland

12:30-1:45 p.m.  Lunch and Poster Viewing

1:45-2:45 p.m.  Lightning Poster Session  Luc Buee

Moderator: Luc Buee

2:45-2:50 p.m.  Second Plenary Introduction  Kathryn Bowles
February 12-13, 2020 | Washington, D.C.

**Second Plenary**
What Genetic and Functional Studies Have Taught Us About the Role of MAPT in Neurodegeneration?

**Session 3: Genetics and Tauopathies**

- 3:20-3:40 p.m. Molecular Drivers of Primary Tauopathy
  - Celeste Karch

- 3:40-4 p.m. Common Genetic Features in Primary Tauopathies
  - John Hardy

- 4-4:20 p.m. TBD
  - Aled Edwards

- 4:20-4:40 p.m. Imaging and Cognitive Profile of Colombian Families With Taupathies
  - Yakeel Quiroz

**Panel Discussion**
Moderator: Martin Citron

**Panel and Debate**
Moderator: Samantha Budd
Propagation vs. Selective Vulnerability

**Lightning Rounds for CUREPSP**
Moderator: Larry Golbe

**Close of Day One**

**Agenda Strawman – DAY 2**

**Breakfast**

**Open of Day Two**

*Sponsorship Information*

- **Reception Sponsored by the Rainwater Prize**
  - (All are welcome)

*Sponsor Information*
## Tau 2020
February 12-13, 2020 | Washington, D.C.

### Session 4: Molecular Mechanism for Therapeutic Approaches

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45-9:05 a.m.</td>
<td>Routing Tau Between and Within Cells</td>
<td>Kenneth S. Kosik</td>
</tr>
<tr>
<td>9:05-9:25 a.m.</td>
<td>TBD</td>
<td>Sarah DeVos</td>
</tr>
<tr>
<td>9:25-9:45 a.m.</td>
<td>TBD</td>
<td>Eliezer Masliah</td>
</tr>
<tr>
<td>9:45-10:05 a.m.</td>
<td>PROTAC</td>
<td>Angela Cacace</td>
</tr>
<tr>
<td>10:05-10:25 a.m.</td>
<td>Panel Discussion</td>
<td>Mike Hutton</td>
</tr>
<tr>
<td>10:25-10:50 a.m.</td>
<td>Break and Checkout</td>
<td></td>
</tr>
<tr>
<td>10:50-11:50 a.m.</td>
<td>Rainwater Prize Ceremony and Winners’ Keynotes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tau Therapeutics: Translational Challenges in Moving From Bench to Bedside</td>
<td></td>
</tr>
<tr>
<td>11:50 a.m.-</td>
<td>Second Lightning Poster Session</td>
<td></td>
</tr>
<tr>
<td>12:50 p.m.</td>
<td>Moderator: Hui Zheng</td>
<td></td>
</tr>
<tr>
<td>12:50-2 p.m.</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>2:05-2:35 p.m.</td>
<td>Third Plenary</td>
<td>Adam Boxer</td>
</tr>
<tr>
<td>2:35-2:55 p.m.</td>
<td>Tau Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Initial Results From a Phase 2 Study of</td>
<td>Mike Gold</td>
</tr>
<tr>
<td></td>
<td>the Pan-Tau Antibody 8E12 in Patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>With Progressive Supranuclear Palsy</td>
<td></td>
</tr>
<tr>
<td>2:55-3:15 p.m.</td>
<td>ASOs</td>
<td>Tim Miller</td>
</tr>
<tr>
<td>3:15-3:35 p.m.</td>
<td>Clinical Overview of Tau Targets</td>
<td>Cath Mummery</td>
</tr>
<tr>
<td>3:35-3:55 p.m.</td>
<td>Industry Overview of Tau Targets</td>
<td>Philipp von Rosenthiel</td>
</tr>
<tr>
<td>3:55-4:15 p.m.</td>
<td>Panel Discussion</td>
<td>Howard Feldman</td>
</tr>
<tr>
<td>4:15-4:40 p.m.</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
4:40-5:15 p.m.  Panel Session
Early Stage Investment in Tau Therapeutics
Moderators: Pat Brannelly
Stacie Weninger (FBRI)
James Mutamba (Longwood Fund)
Dirk Beher (Asceneuron)

5:15 p.m.  Closing Remarks